Is Dynavax Technologies (DVAX) Pricing Reflect Its Recent Rally And DCF Implied Upside Potential

Simply Wall St.01-14

If you are wondering whether Dynavax Technologies is still good value at around US$15.72, the key question is how its current share price lines up against its underlying business. The stock has seen ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603610384?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-01-14 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603610384","market":"hk","top_or_hot":-1,"title":"Is Dynavax Technologies (DVAX) Pricing Reflect Its Recent Rally And DCF Implied Upside Potential","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Dynavax Technologies is still good value at around US$15.72, the key question is how its current share price lines up against its underlying business. The stock has seen ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/is-dynavax-technologies-dvax-pricing-reflect-its-recent-rall\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Dynavax Technologies (DVAX) Pricing Reflect Its Recent Rally And DCF Implied Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Dynavax Technologies (DVAX) Pricing Reflect Its Recent Rally And DCF Implied Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-14 19:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/is-dynavax-technologies-dvax-pricing-reflect-its-recent-rall><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Dynavax Technologies is still good value at around US$15.72, the key question is how its current share price lines up against its underlying business. The stock has seen ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/is-dynavax-technologies-dvax-pricing-reflect-its-recent-rall\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DVAX","symbol_name":"德纳维制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/is-dynavax-technologies-dvax-pricing-reflect-its-recent-rall","article_id":"2603610384","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/is-dynavax-technologies-dvax-pricing-reflect-its-recent-rall","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603610384","pubTimestamp":1768389875,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Dynavax Technologies is still good value at around US$15.72, the key question is how its current share price lines up against its underlying business.\nThe stock has seen returns of 1.9% over the last 7 days, 45.6% over the last 30 days, 2.2% year to date, 26.0% over 1 year and 38.5% over 3 years, with a very large 5 year return that points to a stock many investors are watching closely.\nThese moves sit against a backdrop of ongoing attention on Dynavax...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DVAX":"德纳维制药","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4139":"生物科技"},"translate_title":"Dynavax Technologies(DVAX)的定价是否反映了其近期的上涨和DCF隐含的上涨潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1.5,"DVAX":1.5},"content_text":"If you are wondering whether Dynavax Technologies is still good value at around US$15.72, the key question is how its current share price lines up against its underlying business. The stock has seen returns of 1.9% over the last 7 days, 45.6% over the last 30 days, 2.2% year to date, 26.0% over 1 year and 38.5% over 3 years, with a very large 5 year return that points to a stock many investors are watching closely. These moves sit against a backdrop of ongoing attention on Dynavax Technologies as a vaccines and immunology player. Investors are weighing how its product portfolio and partnerships might shape the business over time. That context helps explain why the market has been quick to react, both to company specific updates and to broader sentiment around biotech names. On our checks, Dynavax Technologies scores 4 out of 6 on valuation, as shown by its valuation score. Next we will look at what different valuation approaches say about the stock and then finish with a framework that many investors find even more useful for judging value.  Find out why Dynavax Technologies's 26.0% return over the last year is lagging behind its peers. AdvertisementApproach 1: Dynavax Technologies Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and then discounting those back to today’s value. For Dynavax Technologies, the model here is a 2 Stage Free Cash Flow to Equity approach, using free cash flow available to shareholders. The latest twelve month free cash flow is about $84.2 million. Analyst inputs and extrapolated estimates suggest free cash flow of $79 million in 2026 and $183 million by 2030, with further projections out to 2035 based on Simply Wall St assumptions rather than direct analyst forecasts. Bringing all those projected cash flows back to today and adding them up gives an estimated intrinsic value of about US$38.32 per share. Compared with a recent share price around US$15.72, the model implies an intrinsic discount of roughly 59.0%, which indicates that the shares appear significantly undervalued on this DCF view. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Dynavax Technologies is undervalued by 59.0%. Track this in your watchlist or portfolio, or discover 885 more undervalued stocks based on cash flows. DVAX Discounted Cash Flow as at Jan 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Dynavax Technologies. Approach 2: Dynavax Technologies Price vs Sales For companies where profits can be uneven, investors often look at the Price to Sales, or P/S, ratio because sales are usually more stable than earnings. It gives you a simple way to relate what you are paying for each dollar of revenue. Growth expectations and risk still matter here. A higher growth outlook or lower perceived risk can support a higher P/S multiple, while slower growth or higher uncertainty usually aligns with a lower, more conservative range. Dynavax Technologies currently trades on a P/S ratio of 5.41x. The broader Biotechs industry average is 12.51x, and the peer group referenced here sits at 38.56x. Simply Wall St also calculates a Fair Ratio of 4.13x for Dynavax Technologies. This Fair Ratio is a proprietary estimate of the P/S multiple that might fit the company, taking into account factors such as earnings growth, industry, profit margin, market cap and risks. Because it is tailored to the company, the Fair Ratio can be more informative than a simple comparison against peers or an industry average, which might have very different risk and growth profiles. With Dynavax Technologies trading above the 4.13x Fair Ratio, the shares appear expensive on this P/S view. Result: OVERVALUED NasdaqGS:DVAX P/S Ratio as at Jan 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1443 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Dynavax Technologies Narrative Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St's Community page you can use Narratives, where you set out your story for Dynavax Technologies, link that story to your own revenue, earnings and margin forecasts, translate those into a fair value, then compare that fair value to the current share price. The Narrative updates automatically as new news or earnings arrive. One investor might back a higher fair value closer to US$32.00 based on confidence in HEPLISAV B, the pipeline and buybacks, while another might anchor nearer US$11.00 if they focus more on concentration, regulatory and pricing risks. Both can clearly see how their assumptions differ and what that means for their buy or sell decisions. Do you think there's more to the story for Dynavax Technologies? Head over to our Community to see what others are saying! NasdaqGS:DVAX 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603610384","isCrawlerRequest":true}